Literature DB >> 19208558

Thrombin-cleaved osteopontin in synovial fluid of subjects with rheumatoid arthritis.

Masahiro Hasegawa1, Yutaka Nakoshi, Takahiro Iino, Akihiro Sudo, Tatsuya Segawa, Masahiro Maeda, Toshimichi Yoshida, Atsumasa Uchida.   

Abstract

OBJECTIVE: Osteopontin (OPN) is an extracellular matrix glycoprotein that has been recognized as a potential inflammatory cytokine. The function of OPN is modulated by protease digestion, and a thrombin-cleaved form of OPN is involved in the pathogenesis of various inflammatory disorders. We examined thrombin-cleaved OPN products in synovial fluid from patients with rheumatoid arthritis (RA) and osteoarthritis (OA).
METHODS: Synovial fluid samples were obtained from knees of 20 patients with RA and 111 patients with OA. Thrombin-cleaved OPN product was determined using Western blotting. Levels of thrombin- cleaved and full-length OPN in synovial fluid were determined by ELISA. Synovia were analyzed by immunohistochemistry using an antibody specific to the thrombin-cleaved form.
RESULTS: Immunoblotting showed the presence of thrombin-cleaved OPN in synovial fluid from patients with RA and OA. ELISA results showed no difference between concentrations of full-length OPN in the synovial fluid of RA and OA patients; however, thrombin-cleaved OPN concentrations in RA synovial fluid samples were roughly 30-fold higher compared with OA samples (p < 0.001). Synovial fluid concentrations of thrombin-cleaved OPN in RA did not correlate with C-reactive protein levels. Immunohistochemistry of the synovium showed stronger reactivity in RA than in OA samples.
CONCLUSION: Local generation of thrombin-cleaved OPN was increased in RA joints. Thrombin-cleaved OPN may be a useful biochemical marker of RA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19208558     DOI: 10.3899/jrheum.080753

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  17 in total

1.  Serum level of osteopontin as an inflammatory marker does not indicate disease activity or responsiveness to therapeutic treatments in patients with rheumatoid arthritis.

Authors:  Hye-In Ji; Sang-Hoon Lee; Ran Song; Hyung-In Yang; Yeon-Ah Lee; Seung-Jae Hong; Somi Kim; Yong-Beom Park; Soo-Kon Lee; Myung Chul Yoo; Kyoung Soo Kim
Journal:  Clin Rheumatol       Date:  2013-09-01       Impact factor: 2.980

2.  Osteopontin undergoes polymerization in vivo and gains chemotactic activity for neutrophils mediated by integrin alpha9beta1.

Authors:  Norihisa Nishimichi; Hiromi Hayashita-Kinoh; Chun Chen; Haruo Matsuda; Dean Sheppard; Yasuyuki Yokosaki
Journal:  J Biol Chem       Date:  2011-02-14       Impact factor: 5.157

Review 3.  TRPV4 as a therapeutic target for joint diseases.

Authors:  Amy L McNulty; Holly A Leddy; Wolfgang Liedtke; Farshid Guilak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-12-18       Impact factor: 3.000

Review 4.  Association of osteopontin with osteoarthritis.

Authors:  Chao Cheng; Shuguang Gao; Guanghua Lei
Journal:  Rheumatol Int       Date:  2014-05-08       Impact factor: 2.631

5.  Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis.

Authors:  Laura Bazzichi; Lorenzo Ghiadoni; Alessandra Rossi; Melania Bernardini; Mario Lanza; Francesca De Feo; Camillo Giacomelli; Ilaria Mencaroni; Katia Raimo; Marco Rossi; Anna Maria Mazzone; Stefano Taddei; Stefano Bombardieri
Journal:  Mol Med       Date:  2009-06-18       Impact factor: 6.354

Review 6.  Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies.

Authors:  Lunxiu Qin
Journal:  Front Med       Date:  2014-01-25       Impact factor: 4.592

Review 7.  Role of osteopontin in rheumatoid arthritis.

Authors:  Fangjie Zhang; Wei Luo; Yusheng Li; Shuguang Gao; Guanghua Lei
Journal:  Rheumatol Int       Date:  2014-08-28       Impact factor: 2.631

8.  Serum osteopontin, but not OPN gene polymorphism, is associated with LVH in essential hypertensive patients.

Authors:  Xuwei Hou; Zhaohui Hu; Xiaohua Huang; Yan Chen; Xiuying He; Haiying Xu; Ningfu Wang
Journal:  J Mol Med (Berl)       Date:  2013-12-27       Impact factor: 4.599

Review 9.  Location, location, location: how the tissue microenvironment affects inflammation in RA.

Authors:  Christopher D Buckley; Caroline Ospelt; Steffen Gay; Kim S Midwood
Journal:  Nat Rev Rheumatol       Date:  2021-02-01       Impact factor: 20.543

10.  Osteopontin level in synovial fluid is associated with the severity of joint pain and cartilage degradation after anterior cruciate ligament rupture.

Authors:  Mika Yamaga; Kunikazu Tsuji; Kazumasa Miyatake; Jun Yamada; Kahaer Abula; Young-Jin Ju; Ichiro Sekiya; Takeshi Muneta
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.